세계의 줄기세포 제조 시장 예측(-2027년)

Market Overview

The Stem Cell Manufacturing Market is projected to encounter a critical build yearly development rate (CAGR) of 13.16% during the figure time frame. Stem cell treatment offers likely medicines for many already hopeless infections, including AIDS, cardiovascular illnesses, neurodegenerative sicknesses, autoimmune infections, muscular circumstances, and wound mending. Stem cells are progressively being utilized to supplant harmed neurons brought about by spinal line wounds, Parkinson's illness, Alzheimer's infection, and other neurological issues. They likewise assume an urgent part in delivering insulin for diabetes patients and helping with the recovery of harmed tissues and organs.

Intriguing sicknesses, which influence a little level of the populace, are frequently disregarded because of their restricted patient populace and the significant expenses related to creating therapies. These sicknesses include uncommon tumors, hereditary illnesses, irresistible tropical infections, and degenerative infections. As per information distributed by the Food and Medication Organization (FDA) in February 2020, there are roughly 7,000 uncommon sicknesses, with over a portion of them influencing kids. Be that as it may, just 5% of these infections have FDA-endorsed medicines. Subsequently, the rising consciousness of stem cell applications for treating different infections and the developing rate of uncommon illnesses are central point adding to the market's development.

Market Segmentation

Products including stem cell lines, equipment, culture media, and consumables can be used to segment the stem cell manufacturing market. Mesenchymal stem cells (MSCs) induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), hematopoietic stem cells (HSCs), and other stem cell types are subcategories of stem cell lines. Bioreactors, incubators, cell sorters, and other tools are examples of instruments. Applications such as research, target identification, stem cell-based therapy, and cell and tissue banking are also used to segment the market data. The worldwide stem cell market is segmented into hospitals, pharmaceutical and biotechnology firms, stem cell banks, and other entities based on end users.

Regional analysis

North America held the biggest market share in 2021 in the stem cell manufacturing market. This can be credited to the rising commonness of constant sicknesses, including malignant growth, cardiovascular issues, neurological problems, gastrointestinal illnesses, and other ongoing circumstances. In the US alone, the Public Malignant Growth Organization and the Public

Europe positions second in the stem cell manufacturing market, for the most part because of the accessibility of cutting-edge therapy offices, government support for medical services area improvement, a developing geriatric populace, and a rising number of cases including constant and neurological problems.

The Asia-Pacific region is supposed to display critical development in the stem cell manufacturing market from2018 to 2027. Factors adding to this development remember upgrades for the medical care framework, expanded reception of stem cell treatment therapies, the presence of agreement makers, and a rising commonness of disease in the region. China at present holds the biggest market share in the Asia-Pacific region, while India shows the most elevated development rate.

Major Players

Prominent players in the stem cell manufacturing market include Fujifilm Holdings Corporation (US), AbbVie, Inc. (US), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson, and Company (US), Thermo Fisher Scientific, Inc. (US), Lonza Group (Switzerland), Bristol-Myers Squibb Company (US), GlaxoSmithKline Plc (UK), Sartorius AG (Germany), Merck KGaA (Germany), and others.

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 SCOPE OF THE STUDY
• 2.2 RESEARCH OBJECTIVE
• 2.3 MARKET STRUCTURE
• 2.4 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 GROWING AWARENESS REGARDING THE USAGE OF STEM CELLS FOR TREATING VARIOUS DISEASES
  • 4.2.2 INCREASING PREVALENCE OF RARE DISEASES
  • 4.2.3 TECHNOLOGICAL ADVANCEMENTS IN STEM CELL MANUFACTURING
• 4.3 RESTRAINTS
  • 4.3.1 RISKS ASSOCIATED WITH UNPROVEN STEM CELL TREATMENTS
  • 4.3.2 HIGHER OPERATIONAL COSTS ASSOCIATED WITH STEM CELL MANUFACTURING AND BANKING
• 4.4 OPPORTUNITIES
  • 4.4.1 INCREASING PUBLIC AND PRIVATE FUNDING FOR STEM CELL-BASED RESEARCH

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D AND DESIGNING
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION & SALES
  • 5.1.4 POST-SALES REVIEW
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 BARGAINING POWER OF BUYERS
  • 5.2.4 INTENSITY OF RIVALRY
  • 5.2.5 THREAT OF SUBSTITUTES
• 5.3 IMPACT OF COVID-19
  • 5.3.1 IMPACT ON SUPPLY CHAIN
  • 5.3.2 IMPACT ON PRODUCTION
  • 5.3.3 IMPACT ON DEMAND-SUPPLY GAP ANALYSIS
  • 5.3.4 IMPACT ON R&D

6 GLOBAL STEM CELL MANUFACTURING MARKET, BY PRODUCT

• 6.1 OVERVIEW
• 6.2 STEM CELL LINES
• 6.3 INSTRUMENTS
• 6.4 CULTURE MEDIA
• 6.5 CONSUMABLES

7 GLOBAL STEM CELL MANUFACTURING MARKET, BY APPLICATION

• 7.1 OVERVIEW
• 7.2 RESEARCH
• 7.3 TARGET IDENTIFICATION
• 7.4 STEM CELL-BASED THERAPY
• 7.5 CELL AND TISSUE BANKING

8 GLOBAL STEM CELL MANUFACTURING MARKET, BY END USER

• 8.1 OVERVIEW
• 8.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
• 8.3 HOSPITALS
• 8.4 STEM CELL BANKS
• 8.5 OTHERS

9 GLOBAL STEM CELL MANUFACTURING MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 FRANCE
  • 9.3.3 UK
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 SOUTH KOREA
  • 9.4.5 AUSTRALIA
  • 9.4.6 REST OF ASIA-PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 MIDDLE EAST
  • 9.5.2 AFRICA
  • 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 COMPETITIVE BENCHMARKING
• 10.3 MAJOR GROWTH STRATEGY IN STEM CELL MANUFACTURING MARKET
• 10.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN STEM CELL MANUFACTURING MARKET
• 10.5 KEY DEVELOPMENT ANALYSIS
• 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.6.1 PRODUCT APPROVALS AND PRODUCT LAUNCHES
  • 10.6.2 PARTNERSHIP/COLLABORATION
  • 10.6.3 BUSINESS EXPANSIONS/AGREEMENTS
  • 10.6.4 MERGERS & ACQUISITIONS

11 COMPANY PROFILES

• 11.1 ABBVIE, INC.
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 BIO-RAD LABORATORIES, INC.
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 FUJIFILM HOLDINGS CORPORATION (FUJIFILM CELLULAR DYNAMICS, INC.)
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 KEY STRATEGIES
• 11.4 BECTON DICKINSON AND COMPANY
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL ANALYSIS
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 KEY STRATEGIES
• 11.5 THERMO FISHER SCIENTIFIC INC.
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL ANALYSIS
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 SWOT ANALYSIS
  • 11.5.6 KEY STRATEGIES
• 11.6 LONZA GROUP
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL ANALYSIS
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 KEY STRATEGIES
• 11.7 BRISTOL-MYERS SQUIBB COMPANY
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 KEY STRATEGIES
• 11.8 GLAXOSMITHKLINE PLC
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 SWOT ANALYSIS
  • 11.8.6 KEY STRATEGIES
• 11.9 SARTORIUS AG
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 KEY STRATEGIES
• 11.10 MERCK KGAA
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 KEY STRATEGIES
• 11.11 TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • 11.11.1 COMPANY OVERVIEW
  • 11.11.2 FINANCIAL OVERVIEW
  • 11.11.3 PRODUCTS OFFERED
  • 11.11.4 KEY DEVELOPMENTS
  • 11.11.5 SWOT ANALYSIS
  • 11.11.6 KEY STRATEGIES

12 APPENDIX

• 12.1 REFERENCES
• 12.2 RELATED REPORTS